Wedbush Assumes Coverage on Medivation (MDVN) at Outperform; An Exciting Time for Prostate Cancer
Tweet Send to a Friend
Wedbush assumes coverage on Medivation (NASDAQ: MDVN) with a Outperform. PT $25.
Wedbush analyst says, "Medivation has two major assets ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Medivation has two major assets ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
